Clinical trial

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

NCT07649421

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-15

PhasePHASE2

Study timeline

Study start (estimated)2026-09-15Date precision: day

Registry last updated2026-09-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)unresolved

Interventions

Stereotactic Body Radiotherapy (SBRT)RADIATION

Darolutamide 600 mg twice dailyDRUG

Androgen Deprivation Therapy (ADT)DRUG

Sponsors & collaborators

West China Hospitallead sponsor

Bayercollaborator

Mapped research locations

ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07649421 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.